A comparative study on the solid phase capture--platelet test, platelet adhesion immunofluorescence test and lymphocytotoxic test.

J Jin; X J Lin; R Dorner; V Sachs

Home/Archive/PubMed

PubMed · 8243126

A comparative study on the solid phase capture--platelet test, platelet adhesion immunofluorescence test and lymphocytotoxic test.

J Jin·X J Lin·R Dorner·V Sachs

View original source ↗Export metadata ↓

Abstract

The sensitivity, specificity and reproducibility of the solid phase capture-platelet test (CPT) were compared with those of the platelet adhesion immunofluorescence test (PAIFT) and the lymphocytotoxic test (LCT). This study shows that CPT has a higher sensitivity than PAIFT (P < 0.001) and LCT (P < 0.01). The specificity was 86% lower than LCT (100%) (P < 0.01). Both the CPT test and PAIFT were comparable with regard to reproducibility (100%, 92%). The solid phase assay is easier to handle than PAIFT and LCT, allowing identification of HLA as well as of platelet specific antibodies. It is an efficient antibody screening test.

Explore related subjects

Antibody Specificity Blood Platelets Fluorescent Antibody Technique Humans Immunologic Tests Isoantibodies Platelet Adhesiveness Purpura, Thrombocytopenic Sensitivity and Specificity Comparative Study Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J Jin, X J Lin, R Dorner, V Sachs. 1993. A comparative study on the solid phase capture--platelet test, platelet adhesion immunofluorescence test and lymphocytotoxic test.. https://pubmed.ncbi.nlm.nih.gov/8243126/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody.

In this study, we use a novel glycan array to analyze the glycan-binding antibody repertoire in a pool of affinity-purified IgG collected from a healthy human population. The glycan array used is based on mono- and oligosaccharides covalently linked to the surface via a long linker at their reducing ends. They are thus presented to the medium with a well-defined orientation and are accessible for specific binding by glycan-binding proteins, such as antibodies and lectins. A novel anticellulose antibody was detected that binds specifically to beta4-linked saccharides with a preference for glucopyranose over galactopyranose residues. We also found previously known antiglycan antibodies against mono- and oligosaccharides that are constituents of commonly occurring bacterial polysaccharides. We propose that this array can facilitate high-throughput screening of glycan-binding proteins and the search for biomarkers for personalized medicine.

Antibody Specificity↗

PubMed2003

Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis.

BACKGROUND: Phospholipid transfer protein (PLTP) plays an important role in HDL particle metabolism and may modulate hepatic secretion of apolipoprotein B-containing lipoproteins. However, whether PLTP might participate directly in human atherosclerotic lesion formation is unknown. METHODS AND RESULTS: The cellular and extracellular distributions of PLTP were determined in normal and atherosclerotic human coronary lesions with a monoclonal antibody to human PLTP. Cell types (smooth muscle cells [SMCs] or macrophages), apolipoproteins (apoA-I, apoB, and apoE), and extracellular matrix proteoglycans (biglycan and versican) were identified on adjacent sections with monospecific antibodies. Minimal extracellular PLTP was detected in nonatherosclerotic coronary arteries, but extracellular and cellular PLTP immunostaining was widespread in atherosclerotic lesions. PLTP was detected in foam cell SMCs and in foam cell macrophages, which suggests that cellular cholesterol accumulation might increase PLTP expression in both cell types. This was confirmed by in vitro studies demonstrating that cholesterol loading of macrophages leads to 2- to 3-fold increases in PLTP steady-state mRNA levels, protein expression, and activity. PLTP also was detected in an extracellular distribution, colocalizing with apoA-I, apoB, apoE, and the vascular proteoglycan biglycan. In gel mobility shift assays, both active and inactive recombinant PLTP markedly increased HDL binding to biglycan, which suggests that PLTP may mediate lipoprotein binding to proteoglycans independent of its phospholipid transfer activity. CONCLUSIONS: PLTP is present in human atherosclerotic lesions, and its distribution suggests roles for PLTP in both cellular cholesterol metabolism and lipoprotein retention on extracellular matrix.

Antibody Specificity↗

PubMed2003

A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.

The evolution of autologous neutralizing antibodies to sequential human immunodeficiency virus type 1 (HIV-1) isolates was studied in a population of 16 children who were perinatally infected with human immunodeficiency virus type 1. The cohort included seven children with rapid disease progression (RP) and nine who had nonrapid disease progression (NRP). Four of the NRP after 6 months of age harbored viruses that could be neutralized by antibodies found in autologous contemporaneous plasma (titers up to 1:640) while the majority of longitudinally collected viruses from five NRP were resistant to neutralization with contemporaneous plasma. Because of their shorter survival, only five of the RP had studies after 6 months of age; three of the five had neutralizing antibodies to contemporaneous virus isolates and the highest titers were 1:20. The highest titers in RP (up to 1:160) occurred in specimens obtained prior to 6 months of age but these were most likely of maternal origin. Most isolates that were not neutralized by contemporaneous plasma could be neutralized using noncontemporaneous plasma obtained months to years after the virus isolates. These autologous noncontemporaneous neutralizing antibodies persisted for years, had titers that were higher to viruses isolated at younger ages, and were generally more potent in children with NRP than RP. Demonstration of neutralizing antibodies to viruses previously resistant to neutralization by contemporaneous plasma suggests a continuous evolution of virus variants in vivo that are able to escape the effect of neutralizing antibodies.

Antibody Specificity↗